Delving into the Latest Updates on Fosinopril Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dynacil, Eliten, Fosenopril

+ [20]

Target

ACE

Action

inhibitors

Mechanism

ACE inhibitors(Angiotensin-converting enzyme inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Heart FailureHypertension

Inactive Indication-

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Sino-American Shanghai Squibb Pharmaceuticals Ltd.

Inactive Organization

Bristol Myers Squibb Co.

Drug Highest PhaseApproved

First Approval Date

United States (16 May 1991),

Heart FailureHypertension

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC30H46NNaO7P

InChIKeyNIDZYXQFQSHBTG-WATAJHSMSA-N

CAS Registry88889-14-9

View All Structures (2)

AbstractFosinopril (FOS) is an angiotensin-converting enzyme inhibitor that can decrease angiotensin II (Ang II) formation, thereby reducing systemic vasoconstriction. This study investigated the impact of FOS on vascular smooth muscle cell (VSMC) phenotypic transformation in hypertension. Experiments using western blotting revealed that FOS inhibits the Ang II-induced downregulation of α-SMA and SM22α and the upregulation of OPN in VSMCs. In addition, CCK8 assays, EdU staining, and Transwell assays demonstrated that FOS reduces Ang II-induced increases in VSMC cell viability, proliferation, migration, and MMP2 and MMP9 expression. Moreover, immunofluorescence and ELISA experiments showed that FOS suppresses Ang II-induced increases in ROS levels, NAD(P)H activity, and NOX2 and NOX4 expression in VSMCs. Western blotting also indicated that FOS inhibits Ang II-induced increases in TGF-β1 and p-Smad2/3 expression in VSMCs. Finally, FOS mitigates Ang II-induced VSMC proliferation, phenotypic transformation, migration, and oxidative stress by inhibiting the TGF-β1/Smad signaling pathway. In conclusion, these results suggest that FOS could be effective in managing vascular diseases, including hypertension.

01 Nov 2024·Pharmaceutical Chemistry Journal

Antiglycation Efficacy: Unknown Pleiotropicity of Known Drugs

Author: Maslennikova, N. O. ; Sharova, O. V. ; Savirova, T. Yu. ; Lebedev, P. A. ; Zaitseva, E. N.

Aging and age-related diseases, which include the most relevant chronic non-infectious diseases (arterial hypertension, coronary heart disease, type 2 diabetes mellitus), are attributed to the accumulation of advanced glycation end-products (AGEs) in various organs and tissues.Glycation (non-enzymic glycosylation) is the name given to the in vivo reaction of reducing carbohydrates and free amino groups of proteins, lipids, and nucleic acids.It has many neg. biol. effects mediated by disruption of the conformation of structural proteins, enzymes, and nucleic acids at the intracellular level and in the extracellular matrix.The consequences of AGE accumulation are difficult to reverse because of the long half-life and slow elimination of AGEs, which makes the development of technologies aimed at blocking the reactions leading to their formation an urgent and important goal.Currently, pharmacol. is faced with the task of searching for mols. with promising antiglycating properties.Identification of drugs that prevent glycation among well-known drugs in clin. practice is a necessary step in solving this problem.The antiglycation properties of such drugs (metformin, ramipril, telmisartan, etc.) are discussed in this review as a little-known component of their pleiotropy.The drugs are classified according to the mechanism of their antiglycation effect.

01 Nov 2024·The American Journal of Cardiology

ACE Inhibitor and Angiotensin Receptor Blocker Use During Pregnancy: Data From the ESC Registry Of Pregnancy and Cardiac Disease (ROPAC)

Article

Author: Rutz, Tobias ; Roos-Hesselink, Jolien W ; Prokselj, Katja ; Nagy, Edit ; van der Zande, Johanna A ; Baroutidou, Amalia ; Johnson, Mark R ; Muñoz-Ortiz, Edison ; Franx, Arie ; Ramlakhan, Karishma P ; Hall, Roger ; Lipczynska, Magdalena

Angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are not recommended during the second and third trimester because of the significant risk of congenital anomalies associated with their use. However, data are scarce, especially regarding their use in the first trimester and about the impact of stopping just before pregnancy. Our study illustrates the profile of the women who used ACE-Is or ARBs during pregnancy and evaluates the impact on perinatal outcomes. The Registry of Pregnancy and Cardiac Disease is a prospective, global registry of pregnancies in women with structural heart disease. Outcomes were compared between women who used ACE-Is or ARBs and those who did not. Multivariable regression analysis was performed to assess the effect of ACE-I or ARB use on the occurrence of congenital anomalies. ACE-Is (n = 35) and/or ARBs (n = 8) were used in 42 (0.7%) of the 5,739 Registry of Pregnancy and Cardiac Disease pregnancies. Women who used ACE-Is or ARBs more often came from a low-or-middle-income country (57% vs 40%, p = 0.021), had chronic hypertension (31% vs 6%, p <0.001), or a left ventricular ejection fraction <40% (33% vs 4%, p <0.001). In the multivariable analysis, ACE-I use during the first trimester was associated with an increased risk of congenital anomaly (odds ratio 3.2, 95% confidence interval 1.0 to 9.6). Therefore, ACE-Is should be avoided during pregnancy, also in the first trimester, because of a higher risk of congenital anomalies. However, there is no need to stop long before pregnancy. Preconception counseling is crucial to discuss the potential risks of these medications, to evaluate the clinical condition and, if possible, to change or stop the medication.

100 Deals associated with Fosinopril Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00622	Fosinopril Sodium	C09AA09	DB00492

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	China	Sino-American Shanghai Squibb Pharmaceuticals Ltd.	01 Jan 1998
Hypertension	China	Sino-American Shanghai Squibb Pharmaceuticals Ltd.	01 Jan 1998

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2018	Not Applicable	Heart Failure	50	Empagliflozin	ylhenvealb(dwzkglhlio) = dnfgjahphr asclvcqyde (obewdspfzl )	-	26 May 2018
				Fosinopril	ylhenvealb(dwzkglhlio) = ykzwywlxtl asclvcqyde (obewdspfzl )
NCT01669434 (CTgov)	Phase 4	Hypotension	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	vcimynewxg(krbbhibqnx) = lxcialaxxw lljnijzylx (rcoixftaqv, bwxlegwnnr - cdagpqjcbu) View more	-	11 Dec 2017
				ACEI continuation (ACEI Continuation)	vcimynewxg(krbbhibqnx) = gorgsmvkci lljnijzylx (rcoixftaqv, tuvitsufag - iqhbufqwqm) View more